Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept in ESKD patients on hemodialysis
NCT01999582Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2013
- Primary completion
- Aug 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of sotatercept in anemia (2 arms), sponsored by Celgene Corporation. Primary endpoints: Area Under the Serum Concentration-Time Curve Over Dosing Interval (14 Days), Area Under the Serum Concentration-Time Curve From Day 1 to Day 28 and 5 more. Started Nov 2013; status: completed.
02
Drugs
sotatercept
03
Conditions
anemia
Beyond the preview
Go deeper on NCT01999582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01999582.